Molina Healthcare, Inc. (MOH)
USD 309.66
(2.51%)
USD 309.66
(2.51%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.74 Billion USD | 12.01% |
| 2022 | 1.34 Billion USD | 38.28% |
| 2021 | 1.12 Billion USD | -2.17% |
| 2020 | 1.15 Billion USD | -0.26% |
| 2019 | 1.14 Billion USD | -11.37% |
| 2018 | 1.24 Billion USD | 235.57% |
| 2017 | -316 Million USD | -7.62% |
| 2016 | 488 Million USD | -18.45% |
| 2015 | 514 Million USD | 57.72% |
| 2014 | 332.69 Million USD | 43.79% |
| 2013 | 214.05 Million USD | 98.16% |
| 2012 | 118.32 Million USD | -47.7% |
| 2011 | 210.2 Million USD | 32.19% |
| 2010 | 165.76 Million USD | 76.4% |
| 2009 | 93.97 Million USD | -36.47% |
| 2008 | 146.29 Million USD | 17.12% |
| 2007 | 126.29 Million USD | 29.82% |
| 2006 | 97.28 Million USD | 58.69% |
| 2005 | 60.9 Million USD | -35.65% |
| 2004 | 95.26 Million USD | 28.8% |
| 2003 | 74.08 Million USD | -93.74% |
| 2002 | 1.18 Billion USD | 2146.99% |
| 2001 | 52.62 Million USD | 99.91% |
| 2000 | 26.32 Million USD | 29.66% |
| 1999 | 19.11 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 471 Million USD | 31.2% |
| 2024 Q2 | 480 Million USD | 1.91% |
| 2024 Q3 | 514 Million USD | 7.08% |
| 2023 Q3 | 401 Million USD | -17.32% |
| 2023 Q4 | 359 Million USD | -10.47% |
| 2023 Q1 | 499 Million USD | 38.61% |
| 2023 Q2 | 485 Million USD | -2.81% |
| 2023 FY | - USD | 12.01% |
| 2022 Q1 | 412 Million USD | 104.98% |
| 2022 Q3 | 380 Million USD | -6.17% |
| 2022 Q4 | 360 Million USD | -5.26% |
| 2022 FY | - USD | 38.28% |
| 2022 Q2 | 405 Million USD | -1.7% |
| 2021 Q4 | 201 Million USD | -20.55% |
| 2021 Q1 | 368 Million USD | 250.48% |
| 2021 FY | - USD | -2.17% |
| 2021 Q2 | 304 Million USD | -17.39% |
| 2021 Q3 | 253 Million USD | -16.78% |
| 2020 Q2 | 440 Million USD | 49.66% |
| 2020 FY | - USD | -0.26% |
| 2020 Q1 | 294 Million USD | 11.36% |
| 2020 Q4 | 105 Million USD | -66.35% |
| 2020 Q3 | 312 Million USD | -29.09% |
| 2019 FY | - USD | -11.37% |
| 2019 Q1 | 311 Million USD | -14.33% |
| 2019 Q2 | 303 Million USD | -2.57% |
| 2019 Q4 | 264 Million USD | -4.35% |
| 2019 Q3 | 276 Million USD | -8.91% |
| 2018 FY | - USD | 235.57% |
| 2018 Q4 | 363 Million USD | 27.82% |
| 2018 Q2 | 381 Million USD | 39.05% |
| 2018 Q1 | 274 Million USD | 179.59% |
| 2018 Q3 | 284 Million USD | -25.46% |
| 2017 Q2 | -125 Million USD | -160.68% |
| 2017 Q1 | 206 Million USD | 862.96% |
| 2017 FY | - USD | -7.62% |
| 2017 Q3 | 209 Million USD | 267.2% |
| 2017 Q4 | 98 Million USD | -53.11% |
| 2016 Q1 | 133 Million USD | 19.82% |
| 2016 Q3 | 164 Million USD | 9.33% |
| 2016 Q4 | -27 Million USD | -116.46% |
| 2016 Q2 | 150 Million USD | 12.78% |
| 2016 FY | - USD | -18.45% |
| 2015 Q2 | 145.16 Million USD | 26.43% |
| 2015 Q4 | 111 Million USD | -22.59% |
| 2015 Q3 | 143.4 Million USD | -1.21% |
| 2015 Q1 | 114.81 Million USD | -12.62% |
| 2015 FY | - USD | 57.72% |
| 2014 FY | - USD | 43.79% |
| 2014 Q4 | 131.39 Million USD | 80.67% |
| 2014 Q3 | 72.72 Million USD | 11.72% |
| 2014 Q2 | 65.09 Million USD | 13.6% |
| 2014 Q1 | 57.3 Million USD | 147.54% |
| 2013 Q4 | 23.15 Million USD | -52.83% |
| 2013 Q2 | 65.05 Million USD | -26.93% |
| 2013 Q3 | 49.07 Million USD | -24.56% |
| 2013 Q1 | 89.02 Million USD | 18.74% |
| 2013 FY | - USD | 98.16% |
| 2012 Q3 | 27.46 Million USD | 169.37% |
| 2012 Q4 | 74.96 Million USD | 172.95% |
| 2012 Q2 | -39.59 Million USD | -176.5% |
| 2012 Q1 | 51.75 Million USD | 782.36% |
| 2012 FY | - USD | -47.7% |
| 2011 Q2 | 47.91 Million USD | -2.99% |
| 2011 FY | - USD | 32.19% |
| 2011 Q4 | 5.86 Million USD | -88.58% |
| 2011 Q3 | 51.37 Million USD | 7.22% |
| 2011 Q1 | 49.39 Million USD | -15.7% |
| 2010 FY | - USD | 76.4% |
| 2010 Q2 | 33.43 Million USD | 9.61% |
| 2010 Q1 | 30.49 Million USD | 642.61% |
| 2010 Q3 | 46.52 Million USD | 39.17% |
| 2010 Q4 | 58.59 Million USD | 25.93% |
| 2009 FY | - USD | -36.47% |
| 2009 Q1 | 29.62 Million USD | -9.0% |
| 2009 Q2 | 30.65 Million USD | 3.49% |
| 2009 Q3 | 26.45 Million USD | -13.71% |
| 2009 Q4 | 4.1 Million USD | -84.47% |
| 2008 Q2 | 33.25 Million USD | 0.73% |
| 2008 Q1 | 33 Million USD | -10.21% |
| 2008 FY | - USD | 17.12% |
| 2008 Q4 | 32.54 Million USD | -16.42% |
| 2008 Q3 | 38.94 Million USD | 17.12% |
| 2007 FY | - USD | 29.82% |
| 2007 Q3 | 35.89 Million USD | -96.63% |
| 2007 Q2 | 1.06 Billion USD | 4519.88% |
| 2007 Q1 | 23.03 Million USD | -10.25% |
| 2007 Q4 | 36.76 Million USD | 2.41% |
| 2006 Q1 | 18.91 Million USD | -5.21% |
| 2006 Q3 | 26.09 Million USD | -1.95% |
| 2006 Q4 | 25.66 Million USD | -1.62% |
| 2006 FY | - USD | 58.69% |
| 2006 Q2 | 26.61 Million USD | 40.68% |
| 2005 FY | - USD | -35.65% |
| 2005 Q2 | -937 Thousand USD | -103.43% |
| 2005 Q1 | 27.29 Million USD | -6.66% |
| 2005 Q4 | 19.95 Million USD | 33.09% |
| 2005 Q3 | 14.99 Million USD | 1700.21% |
| 2004 Q3 | 27.64 Million USD | 30.49% |
| 2004 Q4 | 29.23 Million USD | 5.76% |
| 2004 FY | - USD | 28.8% |
| 2004 Q2 | 21.18 Million USD | 23.26% |
| 2004 Q1 | 17.18 Million USD | -19.08% |
| 2003 Q1 | 357.52 Million USD | 0.0% |
| 2003 FY | - USD | -93.74% |
| 2003 Q4 | 21.25 Million USD | 10.88% |
| 2003 Q3 | 19.19 Million USD | 1.12% |
| 2003 Q2 | 18.96 Million USD | -94.7% |
| 2002 FY | - USD | 2146.99% |
| 2001 FY | - USD | 99.91% |
| 2000 FY | - USD | 29.66% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Cigna Corporation | 9.98 Billion USD | 82.537% |
| Centene Corporation | 5.61 Billion USD | 68.946% |
| CVS Health Corporation | 18.17 Billion USD | 90.406% |
| Elevance Health Inc. | 10.49 Billion USD | 83.375% |
| Humana Inc. | 4.93 Billion USD | 64.625% |
| Oscar Health, Inc. | -212 Million USD | 922.63% |
| UnitedHealth Group Incorporated | 36.33 Billion USD | 95.2% |